Healius Limited (HLS) Fair Value & Analysis
Healthcare · AU · Market cap A$236M
Fair value as of: Jul 16, 2026
From 16 valuation models · updated yesterday
Share price +1.3% over the past month.
Price vs Fair Value (12 months)
12‑month range A$0.3150 – A$1.04 · fair‑value band A$0.1695 – A$0.3405 · the A$0.4000 price screens above the A$0.2550 fair value. As of Jul 16, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Healius Limited (HLS) currently trades at A$0.4000, while our model-based Fair Value estimate is A$0.2550, implying the stock looks roughly 36.3% overvalued today. We read business quality at 36/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).
Over the trailing twelve months, Healius Limited generated revenue of A$1.4B at a net margin of -12.3%. Revenue grew 3.9% year over year. It earns a return on equity of -69.4%. Net debt stands at A$855M. Fundamentals as of Jul 16, 2026
Our scenario range runs from A$0.1695 (bear case) to A$0.3405 (bull case); at A$0.4000, the current price sits above that range. The share trades about 63% below its 52-week high and 31% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -52% fair-value upside, at -36%, HLS screens cheaper than that median.
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 16, 2026. TTM = trailing twelve months.
About the company
Healius Limited provides medical laboratory and pathology services in Australia. The company provides services under the Laverty Pathology, Dorevitch Pathology, QML Pathology, Western Diagnostic Pathology, Genomic Diagnostic, Vetnostics Pathology, QML Pathology, TML Pathology, Abbott Pathology, IQ Pathology, Kossard, Gastrolab, and Agilex Biolabs brands. It operates medical laboratories and patient collection centers. The company was formerly known as Primary Health Care Limited and changed its name to Healius Limited in December 2018. Healius Limited was incorporated in 1994 and is based in Sydney, Australia.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Healius Limited reported revenue of A$1.3B in FY2025 versus A$1.9B in FY2021, a compound −8.3%/yr. Reported net income was −A$151M in FY2025.
Is HLS fairly valued? → Check now
Similar stocks
10 more Diagnostics & Research stocks, each showing price versus our Fair Value estimate (as of Jul 16, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Thermo Fisher Scientific Inc TMO | $464.01 | $326.81 | -30% |
| Danaher Corporation DAP | €160.60 | €75.98 | -53% |
| WuXi AppTec Co 2359 | HK$152.80 | HK$120.99 | -21% |
| IDEXX Laboratories, Inc IDXX | $562.16 | $190.95 | -66% |
| Lonza Group LZAGY | $61.53 | $15.70 | -74% |
| Agilent Technologies, Inc A | $138.37 | $65.93 | -52% |
| Waters Corporation WAT | $358.25 | $106.31 | -70% |
| Integrated Diagnostics Holdings IDHC | $0.0056 | $0.0100 | +78% |
| IQVIA Holdings IQV | $167.81 | $133.89 | -20% |
| Mettler-Toledo International Inc MTD | $1,133 | $484.94 | -57% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Healius Limited (HLS) undervalued?
What is the fair value of HLS?
What is the quality score of HLS?
What is the revenue of Healius Limited (HLS)?
What is the net profit margin of HLS?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Unlock the full Healius Limited analysis, and try Pro free
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.